Showing results (251-260 of 329) with videos related to
Sort By:
Pageof 33
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|March 5, 2014
BSACI guideline for the diagnosis and management of cow's milk allergyD Luyt, H Ball, N Makwana, et al.Proceedings of the National Academy of Sciences of the United States of America|January 1, 1993
The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genesB Ohana, P A Moore, S M Ruben, et al.Seminars in Oncology|August 1, 1997
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancerH B Neill, A A Miller, G H Clamon, et al.Molecular Cell|December 9, 1998
Broad, but not universal, transcriptional requirement for yTAFII17, a histone H3-like TAFII present in TFIID and SAGAL M Apone, C A Virbasius, F C Holstege, et al.Cancer|November 26, 1999
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group BH L Kindler, C P Belani, J E Herndon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1983
Chronic lymphocytic leukemia and other chronic lymphoid proliferations: surface marker phenotypes and clinical correlationsR O Dillman, J C Beauregard, J W Lea, et al.Cancer Investigation|January 1, 1994
A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group BG Clamon, J Herndon, W Eaton, et al.Clinical Pharmacology and Therapeutics|January 1, 1977
Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassayN R Bachur, C E Riggs, M R Green, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062)A A Miller, G L Rosner, M J Ratain, et al.Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B studyS L Graziano, A Tatum, J E Herndon, et al.Pageof 33